WCLC 2025 - Posters & ePosters-P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 TPS ≥ 50%

P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 TPS ≥ 50%

Asset Subtitle

Balazs Halmos

Meta Tag

Speaker Balazs Halmos

Topic Clinical Trials in Progress